|
1.
|
Jost PJ and Ruland J: Aberrant NF-κB
signaling in lymphoma: mechanisms, consequences, and therapeutic
implications. Blood. 109:2700–2707. 2007.
|
|
2.
|
Keats JJ, Fonseca R, Chesi M, Schop R,
Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio
E, Henry T, et al: Promiscuous mutations activate the noncanonical
NF-κB pathway in multiple myeloma. Cancer Cell. 12:131–144.
2007.PubMed/NCBI
|
|
3.
|
Annunziata CM, Davis RE, Demchenko Y,
Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W,
Dave S, Hurt EM, et al: Frequent engagement of the classical and
alternative NF-κB pathways by diverse genetic abnormalities in
multiple myeloma. Cancer Cell. 12:115–130. 2007.
|
|
4.
|
Hideshima T, Chauhan D, Kiziltepe T, Ikeda
H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson
PG, Carrasco RD and Anderson KC: Biologic sequelae of IκB kinase
(IKK) inhibition in multiple myeloma: therapeutic implications.
Blood. 113:5228–5236. 2009.
|
|
5.
|
Baldwin AS Jr: The NF-κB and IκB proteins:
new discoveries and insights. Annu Rev Immunol. 14:649–683.
1996.
|
|
6.
|
Beg AA and Baldwin AS Jr: The IκB
proteins: multifunctional regulators of Rel NF-κB transcription
factors. Genes Dev. 7:2064–2070. 1993.
|
|
7.
|
Zandi E, Chen Y and Karin M: Direct
phosphorylation of IkappaB by IKKα and IKKβ: discrimination between
free and NF-κB-bound substrate. Science. 281:1360–1363. 1998.
|
|
8.
|
DiDonato JA, Hayakawa M, Rothwarf DM,
Zandi E and Karin M: A cytokine-responsive IκB kinase that
activates the transcription factor NF-κB. Nature. 388:548–554.
1997.
|
|
9.
|
Hideshima T, Richardson P, Chauhan D,
Palombella V, Elliott P, Adams J and Anderson KC: The proteasome
inhibitor PS-341 inhibits growth, induces apoptosis and overcomes
drug resistance in human multiple myeloma cells. Cancer Res.
61:3071–3076. 2001.
|
|
10.
|
Mitsiades N, Mitsiades CS, Poulaki V,
Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA,
Treon SP, Munshi NC, Richardson PG, et al: Molecular sequelae of
proteasome inhibition in human multiple myeloma cells. Proc Natl
Acad Sci USA. 99:14374–14379. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hideshima T, Mitsiades C, Akiyama M,
Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi
NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating
anti-myeloma activity of proteasome inhibitor PS-341. Blood.
101:1530–1534. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Richardson PG, Barlogie B, Berenson J,
Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina
M, Alexanian R, Siegel D, Orlowski RZ, et al: A phase 2 study of
bortezomib in relapsed, refractory myeloma. N Engl J Med.
348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, Reece D, San-Miguel JF, et al: Bortezomib
or high-dose dexamethasone for relapsed multiple myeloma. N Engl J
Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
San Miguel JF, Schlag R, Khuageva NK,
Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT,
Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, et al:
Bortezomib plus melphalan and prednisone for initial treatment of
multiple myeloma. N Engl J Med. 359:906–917. 2008.
|
|
15.
|
Engel RH, Brown JA, Von Roenn JH, O’Regan
RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II
study of single agent bortezomib in patients with metastatic breast
cancer: a single institution experience. Cancer Invest. 25:733–737.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dees EC and Orlowski RZ: Targeting the
ubiquitin-proteasome pathway in breast cancer therapy. Future
Oncol. 2:121–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Schmid P, Kuhnhardt D, Kiewe P,
Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J,
Niederle N, Brossart P, Freier W, Kummel S, et al: A phase I/II
study of bortezomib and capecitabine in patients with metastatic
breast cancer previously treated with taxanes and/or
anthracyclines. Ann Oncol. 19:871–876. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Dees EC, O’Neil BH, Lindley CM, Collichio
F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D and
Orlowski RZ: A phase I and pharmacologic study of the combination
of bortezomib and pegylated liposomal doxorubicin in patients with
refractory solid tumors. Cancer Chemother Pharmacol. 63:99–107.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Awada A, Albanell J, Canney PA, Dirix LY,
Gil T, Cardoso F, Gascon P, Piccart MJ and Baselga J:
Bortezomib/docetaxel combination therapy in patients with
anthracycline-pretreated advanced/metastatic breast cancer: a phase
I/II dose-escalation study. Br J Cancer. 98:1500–1507. 2008.
View Article : Google Scholar
|
|
20.
|
Cresta S, Sessa C, Catapano CV, Gallerani
E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, Maur M, Capri G,
Maccioni E, Tosi D, et al: Phase I study of bortezomib with weekly
paclitaxel in patients with advanced solid tumours. Eur J Cancer.
44:1829–1834. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hideshima T, Ikeda H, Chauhan D, Okawa Y,
Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD
and Anderson KC: Bortezomib induces canonical nuclear factor-κB
activation in multiple myeloma cells. Blood. 114:1046–1052.
2009.
|
|
22.
|
Karin M and Greten FR: NF-kappaB: linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Karin M and Ben-Neriah Y: Phosphorylation
meets ubiquitination: the control of NF-κB activity. Annu Rev
Immunol. 18:621–663. 2000.PubMed/NCBI
|
|
24.
|
Dolcet X, Llobet D, Encinas M, Pallares J,
Cabero A, Schoenenberger JA, Comella JX and Matias-Guiu X:
Proteasome inhibitors induce death but activate NF-κB on
endometrial carcinoma cell lines and primary culture explants. J
Biol Chem. 281:22118–22130. 2006.
|
|
25.
|
Markovina S, Callander NS, O’Connor SL,
Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K and Miyamoto
S: Bortezomib-resistant nuclear factor-κB activity in multiple
myeloma cells. Mol Cancer Res. 6:1356–1364. 2008.
|
|
26.
|
Chauhan D, Li G, Shringarpure R, Podar K,
Ohtake Y, Hideshima T and Anderson KC: Blockade of Hsp27 overcomes
Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma
cells. Cancer Res. 63:6174–6177. 2003.PubMed/NCBI
|
|
27.
|
Hideshima T, Podar K, Chauhan D, Ishitsuka
K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner
G, Nguyen AN, Navas T, et al: p38 MAPK inhibition enhances PS-341
(bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene. 23:8766–8776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Oerlemans R, Franke NE, Assaraf YG, Cloos
J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova
K, Lemos C, van der Heijden JW, Ylstra B, et al: Molecular basis of
bortezomib resistance: proteasome subunit beta5 (PSMB5) gene
mutation and overexpression of PSMB5 protein. Blood. 112:2489–2499.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hideshima T, Chauhan D, Richardson P,
Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A,
Palombella V, Adams J and Anderson KC: NF-kB as a therapeutic
target in multiple myeloma. J Biol Chem. 277:16639–16647. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Garg AK, Hortobagyi GN, Aggarwal BB, Sahin
AA and Buchholz TA: Nuclear factor-κB as a predictor of treatment
response in breast cancer. Curr Opin Oncol. 15:405–411. 2003.
|
|
31.
|
Wu JT and Kral JG: The NF-κB/IκB signaling
system: a molecular target in breast cancer therapy. J Surg Res.
123:158–169. 2005.
|
|
32.
|
Tapia MA, Gonzalez-Navarrete I, Dalmases
A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J,
Mezquita C, Bachs O, Gascon P, Rojo F, et al: Inhibition of the
canonical IKK/NF κB pathway sensitizes human cancer cells to
doxorubicin. Cell Cycle. 6:2284–2292. 2007.PubMed/NCBI
|
